Haven't had much time lately? Here's what you may have missed in the last few months
21 Feb 2017
A year of trastuzumab significantly extends disease-free and overall survival for women treated for primary HER2-positive breast cancer
20 Feb 2017
Patients with urothelial carcinoma resistant to or progressing on platinum chemotherapy may have longer overall survival with pembrolizumab than...
17 Feb 2017
Cholesterol-lowering medication might have a role in reducing breast cancer recurrence among postmenopausal women undergoing endocrine therapy
16 Feb 2017
Combining an epothilone analogue with capecitabine may be effective against anthracycline- and taxane-refractory metastatic breast cancer
15 Feb 2017
A 26-week check-up may be the optimal time point for assessing response to anal cancer chemoradiotherapy
Nicola Fazio provides overview of the current classifications and clinical implications of neuroendocrine tumours (NETs), the role of somatostatin Receptor, what is current practice and treatment of advanced GEP and lung NETs, the key prognostic and predictive factors in NETs, as well as current challenges and future perspectives in the research and treatment of NETs.
10-12 Nov 2016, Lugano, Switzerland